Vascular homing peptides with cell-penetrating properties.

In vivo screening of phage-displayed peptide libraries has revealed extensive molecular heterogeneity in the blood vessels of individual normal tissues and shown that pathological lesions put their signature on the vasculature. In tumors, both blood and lymphatic vessels differ from normal vessels. Moreover, the molecular changes in the vasculature parallel progression in tumor development, hence making the vessels in premalignant lesions distinguishable from normal vessels and from the vessels in malignant tumors of the same tissue. Some of the tumor-homing peptides penetrate into tumor endothelial cells (and tumor cells), but not into endothelial cells in normal tissues or other normal cells. Thus, these cell-penetrating peptides are cell type-specific. Peptides that home to tumor vasculature have been shown to be useful in directing therapeutic agents to experimental tumors. The cell penetrating peptides may be particularly useful in drug delivery because they can take their payload inside the target cells and even into a specific subcellular organelle such as the nucleus.

[1]  C. Lehner,et al.  Major nucleolar proteins shuttle between nucleus and cytoplasm , 1989, Cell.

[2]  Erkki Ruoslahti,et al.  Anti-cancer activity of targeted pro-apoptotic peptides , 1999, Nature Medicine.

[3]  Erkki Ruoslahti,et al.  Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. , 2003, Cancer cell.

[4]  R. Haubner,et al.  Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. , 2004, Current pharmaceutical design.

[5]  E. Ruoslahti,et al.  Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[6]  D. Curiel,et al.  Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. , 2002, Cancer research.

[7]  Erkki Ruoslahti,et al.  Targeting the prostate for destruction through a vascular address , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[8]  E. Ruoslahti Specialization of tumour vasculature , 2002, Nature Reviews Cancer.

[9]  J. K. Hofmeister,et al.  Internalization of anti-nucleolin antibody into viable HEp-2 cells , 2004, Molecular Biology Reports.

[10]  E. Ruoslahti,et al.  Molecular specialization of breast vasculature: A breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[11]  E. Ruoslahti Fibronectin and its receptors. , 1988, Annual review of biochemistry.

[12]  D. Hanahan,et al.  Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. , 2003, Cancer cell.

[13]  E. Ruoslahti,et al.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.

[14]  E. López-Granados,et al.  Cellular Adhesion Mediated by Factor J, a Complement Inhibitor , 1998, The Journal of Biological Chemistry.

[15]  R. Longhi,et al.  Coupling Tumor Necrosis Factor-α with αV Integrin Ligands Improves Its Antineoplastic Activity , 2004, Cancer Research.

[16]  F. Amalric,et al.  Fibroblast Growth Factor-2 Binds to the Regulatory β Subunit of CK2 and Directly Stimulates CK2 Activity toward Nucleolin* , 1996, The Journal of Biological Chemistry.

[17]  R Pasqualini,et al.  Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. , 2000, Cancer research.

[18]  Ülo Langel,et al.  Cell-Penetrating Peptides : Processes and Applications , 2002 .

[19]  Erkki Ruoslahti,et al.  Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels , 2003, The Journal of cell biology.

[20]  Erkki Ruoslahti,et al.  A tumor-homing peptide with a targeting specificity related to lymphatic vessels , 2002, Nature Medicine.

[21]  D. Stolz,et al.  Identification of endothelial cell–surface proteins as targets for diagnosis and treatment of disease , 1996, Nature Medicine.

[22]  A. O’Brien,et al.  Cell Surface-localized Nucleolin Is a Eukaryotic Receptor for the Adhesin Intimin-γ of Enterohemorrhagic Escherichia coliO157:H7* , 2002, The Journal of Biological Chemistry.

[23]  S. Nisole,et al.  The Anti-HIV Cytokine Midkine Binds the Cell Surface-expressed Nucleolin as a Low Affinity Receptor* , 2002, The Journal of Biological Chemistry.

[24]  B. Ding,et al.  Lung Endothelium Targeting for Pulmonary Embolism Thrombolysis , 2003, Circulation.

[25]  Yan Li,et al.  Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy , 2004, Nature.

[26]  M. Hirai,et al.  Nuclear Targeting by the Growth Factor Midkine , 2002, Molecular and Cellular Biology.

[27]  E. Ruoslahti,et al.  An address system in the vasculature of normal tissues and tumors. , 2000, Annual review of immunology.

[28]  Y. Chen,et al.  RGD-Tachyplesin inhibits tumor growth. , 2001, Cancer research.

[29]  Wadih Arap,et al.  Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. , 2002, Cancer research.

[30]  S. Futaki,et al.  Possible Existence of Common Internalization Mechanisms among Arginine-rich Peptides* , 2002, The Journal of Biological Chemistry.

[31]  Erkki Ruoslahti,et al.  A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Peter Carmeliet,et al.  Molecular mechanisms of lymphangiogenesis in health and disease. , 2002, Cancer cell.

[33]  S. Stacker,et al.  Molecular targeting of lymphatics for therapy. , 2004, Current pharmaceutical design.

[34]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[35]  Erkki Ruoslahti,et al.  Organ targeting In vivo using phage display peptide libraries , 1996, Nature.

[36]  R. Petryshyn,et al.  Effect of laminin on the nuclear localization of nucleolin in rat intestinal epithelial IEC-6 cells. , 1998, Biochemical and biophysical research communications.

[37]  D. Brantley-Sieders,et al.  Eph receptor tyrosine kinases in tumor and tumor microenvironment. , 2004, Current pharmaceutical design.